Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (Q24200697)

21 October 2023

Giovanni FM Strippoli

author given names

Giovanni F M

author last names

Strippoli

1 reference

21 October 2023

Angela C Webster

Angela C

Webster

1 reference

21 October 2023

Maleeka Ladhani

Maleeka

Ladhani

1 reference

21 October 2023

Elisabeth M Hodson

Elisabeth M

Hodson

1 reference

23450543

Cochrane Database of Systematic Reviews

21 October 2023

publication date

28 February 2013

0 references

published in

0 references

cites work

Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Comparison of Intravenous Ganciclovir Followed by Oral Acyclovir with Intravenous Ganciclovir Alone for Prevention of Cytomegalovirus and Epstein‐Barr Virus Disease After Liver Transplantation in Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Response to questions regarding the design and results of the IMPACT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

IMPACT Trial Results Should Not Change Current Standard of Care of 100 Days for Cytomegalovirus Prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Ganciclovir Pharmacokinetic Parameters Do Not Change When Extending Valganciclovir Cytomegalovirus Prophylaxis From 100 to 200 Days

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease after Heart Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Cytomegalovirus (CMV) prophylaxis by acyclovir in pre-transplant CMV-positive renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytom

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: a prospective, randomized, controlled, open-label trial1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Prophylaxis against CMV infection in transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Cytomegalovirus pp65 antigen-guided preemptive therapy with ganciclovir in solid organ transplant recipients: a prospective, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Prophylaxis of cytomegalovirus infection in renal transplantation: new data for an old problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Oral valgancyclovir versus intravenous gancyclovir for cytomegalovirus prophylaxis in kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Historical overview of the use of cytomegalovirus hyperimmune globulin in organ transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

A Randomized Prospective Trial of Acyclovir and Immune Globulin Prophylaxis in Liver Transplant Recipients Receiving OKT3 Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients. Longitudinal follow-up of CMV pp65 antigenemia assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

24 Weeks of Valganciclovir Prophylaxis in Children After Renal Transplantation: A 4-Year Experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

WITHDRAWN: Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Infection in organ-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Meta-analysis of prophylaxis of CMV disease in solid organ transplantation: is Ganciclovir a superior agent to Acyclovir?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

International consensus guidelines on the management of cytomegalovirus in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Antiviral medication for preventing cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

A Trial of Vidarabine for Cytomegalovirus Infection in Renal Transplant Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

Controlled trial of prophylactic versus therapeutic use of ganciclovir after liver transplantation in adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

Solid organ transplantation: results and implications of acyclovir use in liver transplants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

Failure of ganciclovir prophylaxis to prevent allograft reinfection following orthotopic liver transplantation for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

Acyclovir in immunocompromised patients with cytomegalovirus disease. A controlled trial at one institution

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

Hyperimmuneglobulin for cytomegalovirus prophylaxis following heart transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

Polymerase chain reaction-triggered preemptive or deferred therapy to control cytomegalovirus-associated morbidity and costs in renal transplant patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

Oral ganciclovir in the prevention of cytomegalovirus infection in postkidney transplant "CMV at risk" recipients: a controlled, comparative study of two regimens (750 mg Bid and 500 mg Bid)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

Effective oral ganciclovir prophylaxis against cytomegalovirus disease in heart transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

A comparative study of 500 mg BID and 250 mg BID of prophylactic oral ganciclovir in post-kidney transplant "CMV at risk" recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

Cytomegalovirus immune globulin after liver transplantation: a cost-effectiveness analysis 1

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal Allografts

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

The prevalence of human herpesvirus-7 in renal transplant recipients is unaffected by oral or intravenous ganciclovir

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

Ganciclovir for treatment of renal transplant-associated primary cytomegalovirus pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

The economic impact of cytomegalovirus infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

CYTOMEGALOVIRUS ANTIGENEMIA DIRECTED PRE-EMPTIVE PROPHYLAXIS WITH ORAL VERSUS I.V. GANCICLOVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN LIVER TRANSPLANT RECIPIENTS1

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: an economic evaluation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

Cytomegalovirus in solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

10.1002/14651858.CD003774.PUB4

Identifiers

DOI

0 references

Fatcat ID

release_i3q4mqjyf5duboughww42ykreu

0 references